AGP Picks
View all

Amwins launches clinical trials insurance product for 115+ countries

an hour ago
Amwins launches clinical trials insurance product for 115+ countries
By AI, Created 14:00 UTC, Nov 19, 2026, AGP -

Amwins introduced an exclusive clinical trials insurance solution through its brokerage arm, aimed at simplifying coverage for international studies that often face licensing hurdles. The product is pre-licensed in more than 115 countries and is designed to speed placement, quoting and document issuance.

Why it matters: - Clinical trials insurance is a regulatory requirement in most territories. - The product is designed to reduce delays when a study needs coverage in multiple countries. - Sponsors may avoid arranging separate local policies, which can add cost and administrative work.

What happened: - Amwins launched an exclusive Clinical Trials insurance solution within its Brokerage division. - The product is available only through Amwins brokers. - Amwins said the solution was developed with a leading Lloyd’s syndicate in the clinical trials market. - The coverage is written on paper pre-licensed in more than 115 countries. - Tom Dillon, executive vice president and national casualty practice leader at Amwins, said the structure is meant to give retail agents a single-placement option for international clinical trial clients.

The details: - The policy includes clinical trials indemnity, no-fault compensation and clinical testing liability coverage. - The solution also includes public liability, products liability, professional liability and medical malpractice coverage. - The product supports clinical research exposures across all phases of study. - Covered study types include sponsor liability for first-in-man and Phase I through Phase IV research. - The coverage also applies to contract research organization exposures, investigator-led studies and university clinical trial programs. - Coverage limits go up to $25 million. - The product has no class limitations. - Amwins said quoting is available the same day. - Amwins said certificates and policy documents can be issued the same day.

Between the lines: - Pre-licensed Lloyd’s paper is the key differentiator here because it can reduce the licensing friction that often slows multinational trials. - The product appears aimed at retail agents and sponsors that need faster placement across multiple jurisdictions. - The same-day turnaround claim suggests Amwins is trying to compete on speed as well as coverage breadth.

What's next: - Amwins is directing interested clients to contact their Amwins broker for more information. - The company is likely to market the product to sponsors, CROs, universities and investigator-led study teams with international exposure. - Broader adoption will depend on how well the new solution performs across varied regulatory environments.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Green Earth Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Green Earth Gazette

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.